ARRAY BIOPHARMA - Home
 
 
About Array  |   Management Team  |   Board of Directors  |   SAB
 
  Year Established 1998  
  Total Employees 250  
  Scientists & Physicians 186  
  Facilities 220,000 square feet  
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly-owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune/Roche) having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013.

Our Strategy
We are building a fully integrated, commercial-stage biopharmaceutical company that discovers, develops and markets safe and effective small molecule drugs to treat patients afflicted with cancer. We intend to accomplish this through the following strategies:

  • Invent targeted small molecule drugs that address critical unmet medical needs for patients fighting cancer.
  • Build internal expertise, including a U.S.-based sales force, to develop and commercialize Array products in hematology/oncology.
  • Seek partnerships to maximize value for our clinical-stage products being developed outside hematology/oncology.

 
 
Email this page
Printer friendly version